Last updated on April 25, 2014 at 1:22 EDT

Oramed Pharmaceuticals to Present at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia, PA, June 8-12, 2012

June 4, 2012

JERUSALEM, June 4, 2012 /PRNewswire/ –

Oramed Pharmaceuticals (OTCBB: ORMP.OB), a developer of oral delivery systems,
announced today that its abstract, “Concomitant oral insulin and exenatide therapies
significantly curb postprandial glucose in pigs,” which reports on the impact of its oral
insulin capsule (ORMD-0801) delivered in combination with its oral exenatide capsule
(ORMD-0901), has been accepted for presentation at the 72nd Scientific Sessions of the
American Diabetes Association (ADA). The work to be presented assessed the safety and
effectiveness of a combination of oral insulin and oral exenatide treatments delivered to
pigs prior to food intake. The drug combination resulted in significantly improved blood
glucose regulation when compared to administration of each drug separately. Dr. Miriam
Kidron, Chief Scientific Officer at Oramed Pharmaceuticals, will be presenting the poster
on Sunday, June 10, 2012, at 11:30am-1:30pm (EDT).

For additional information on the upcoming ADA conference, please visit their website:


About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s
technology is based on over 25 years of research by top research scientists at Jerusalem’s
Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes
through its patented flagship product, an orally ingestible insulin capsule currently in
Phase 2 clinical trials, and with its GLP-1 analog capsule, currently entering Phase 2a
trials. The company’s corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please
visit http://www.oramed.com [../../../../../../../../../User/Downloads/www.oramed.com ]

        Company and Investor Relations Contact:
        Aviva Sherman
        USA: +1-646-240-4193
        Int'l: +972-2-566-0001
        E-mail: aviva@oramed.com

SOURCE Oramed Pharmaceuticals

Source: PR Newswire